Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision
The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
mRNA-1010 demonstrated superior relative vaccine efficacy
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials
Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine
No safety signals related to the vaccine candidate were identified
Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
Subscribe To Our Newsletter & Stay Updated
